Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Irinotecan Hydrochloride

FDA-approved product (injectable, injection), marketed as Camptosar, Irinotecan Hydrochloride, Onivyde.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Irinotecan Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adenocarcinoma
  • Cancer
  • Carcinoma
  • Malignant Pancreatic Neoplasm
  • Neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Topoisomerase 1 (top1) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae54.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Irinotecan Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Irinotecan Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    NCT05863195 · start 2023-10-19

    Registered record
    Registry ID
    NCT05863195
    Conditions
    Metastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Liver; Stage IV Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma
    Interventions
    Bevacizumab; Cetuximab; Computed Tomography; Floxuridine; Fluorouracil; Implantation; Intrahepatic Infusion Procedure; Irinotecan; Leucovorin; Oxaliplatin; Panitumumab; Single Photon Emission Computed Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-10-19
    Completion
    2034-06-30
    Enrolment
    408

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Carcinoma; Metastatic Malignant Neoplasm in the Liver; Stage IV Colorectal Cancer AJCC v8; Unresectable Colorectal Carcinoma
    InterventionBevacizumab; Cetuximab; Computed Tomography; Floxuridine +8 more
    PhasePhase 3
    Registry statusRecruiting

  • Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer (KCSG CO22-12)

    NCT05534087 · start 2022-12-15

    Registered record
    Registry ID
    NCT05534087
    Conditions
    Colon Cancer
    Interventions
    mFOLFIRINOX-FOLFIRI intensified chemotherapy; FOLFOX or CAPOX adjuvant chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-12-15
    Completion
    2030-09-30
    Enrolment
    236

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColon Cancer
    InterventionmFOLFIRINOX-FOLFIRI intensified chemotherapy; FOLFOX or CAPOX adjuvant chemotherapy
    PhasePhase 3
    Registry statusRecruiting

  • Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer

    NCT05358704 · start 2022-05-13

    Registered record
    Registry ID
    NCT05358704
    Conditions
    Cancer of Rectum
    Interventions
    combination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Suspended
    Start
    2022-05-13
    Completion
    2028-01-30
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer of Rectum
    Interventioncombination of drugs (chemoradiation (capecitabine and radiation) + FOLFOXIRI (Oxaliplatin, leucovorin, irinotecan, and fluorouracil)
    PhasePhase 2
    Registry statusSuspended

  • Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

    NCT05065801 · start 2022-01-11

    Registered record
    Registry ID
    NCT05065801
    Conditions
    Metastatic Pancreatic Cancer
    Interventions
    GEMBRAX/FOLFIRINOX Arm A; FOLFIRINOX Arm B
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-01-11
    Completion
    2028-06-30
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Cancer
    InterventionGEMBRAX/FOLFIRINOX Arm A; FOLFIRINOX Arm B
    PhasePhase 2
    Registry statusRecruiting

  • Pancreatic Adenocarcinoma Signature Stratification for Treatment

    NCT04469556 · start 2020-10-14

    Registered record
    Registry ID
    NCT04469556
    Conditions
    Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Advanced Pancreatic Cancer
    Interventions
    Folfirinox; Gemcitabine/nab-paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-10-14
    Completion
    2025-03-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Advanced Pancreatic Cancer
    InterventionFolfirinox; Gemcitabine/nab-paclitaxel
    PhasePhase 2
    Registry statusCompleted

  • A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

    NCT04492033 · start 2020-06-22

    Registered record
    Registry ID
    NCT04492033
    Conditions
    P1b: Advanced Solid Tumors; P2: Biliary Tract Cancer
    Interventions
    CTX-009 (ABL001); Paclitaxel; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2020-06-22
    Completion
    2025-01-09
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionP1b: Advanced Solid Tumors; P2: Biliary Tract Cancer
    InterventionCTX-009 (ABL001); Paclitaxel; Irinotecan
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

    NCT03803553 · start 2020-04-16

    Registered record
    Registry ID
    NCT03803553
    Conditions
    Metastatic Colon Cancer; Stage III Colon Cancer
    Interventions
    FOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol; Trastuzumab + Pertuzumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2020-04-16
    Completion
    2027-12
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colon Cancer; Stage III Colon Cancer
    InterventionFOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol +1 more
    PhasePhase 3
    Registry statusActive not recruiting

  • Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

    NCT03750669 · start 2018-10-20

    Registered record
    Registry ID
    NCT03750669
    Conditions
    Pancreatic Adenocarcinoma Resectable; Neoadjuvant Chemotherapy
    Interventions
    AG regimen; mFolfirinox
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-10-20
    Completion
    2025-03-01
    Enrolment
    324

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Adenocarcinoma Resectable; Neoadjuvant Chemotherapy
    InterventionAG regimen; mFolfirinox
    PhasePhase 3
    Registry statusCompleted

  • VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer

    NCT05540951 · start 2018-06-01

    Registered record
    Registry ID
    NCT05540951
    Conditions
    Colorectal Cancer
    Interventions
    VIC; Bevacizumab Plus Chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-06-01
    Completion
    2022-12-30
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Cancer
    InterventionVIC; Bevacizumab Plus Chemotherapy
    PhasePhase 3
    Registry statusUnknown

  • A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer

    NCT03547804 · start 2018-05-31

    Registered record
    Registry ID
    NCT03547804
    Conditions
    Small-cell Lung Cancer
    Interventions
    Apatinib; chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-31
    Completion
    2020-09-01
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-cell Lung Cancer
    InterventionApatinib; chemotherapy
    PhasePhase 2
    Registry statusCompleted

  • Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer

    NCT03487939 · start 2018-05-01

    Registered record
    Registry ID
    NCT03487939
    Conditions
    Colorectal Neoplasms; Drug Therapy
    Interventions
    FOLFOXIRI
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-05-01
    Completion
    2021-10-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColorectal Neoplasms; Drug Therapy
    InterventionFOLFOXIRI
    PhasePhase 2
    Registry statusUnknown

  • A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

    NCT03522649 · start 2018-04-12

    Registered record
    Registry ID
    NCT03522649
    Conditions
    Previously Treated Metastatic Colorectal Cancer
    Interventions
    Napabucasin; Fluorouracil; Leucovorin; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-04-12
    Completion
    2021-11
    Enrolment
    668

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreviously Treated Metastatic Colorectal Cancer
    InterventionNapabucasin; Fluorouracil; Leucovorin; Irinotecan
    PhasePhase 3
    Registry statusUnknown

  • Post Marketing Surveillance Study for ONIVYDE® in South Korea

    NCT03446872 · start 2018-03-08

    Registered record
    Registry ID
    NCT03446872
    Conditions
    Metastatic Pancreatic Cancer
    Interventions
    ONIVYDE; 5-fluorouracil; Leucovorin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-03-08
    Completion
    2020-08-29
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Pancreatic Cancer
    InterventionONIVYDE; 5-fluorouracil; Leucovorin
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

    NCT03430843 · start 2018-01-26

    Registered record
    Registry ID
    NCT03430843
    Conditions
    Esophageal Squamous Cell Carcinoma (ESCC)
    Interventions
    Tislelizumab; Paclitaxel; Docetaxel; Irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-26
    Completion
    2022-12-28
    Enrolment
    512

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Squamous Cell Carcinoma (ESCC)
    InterventionTislelizumab; Paclitaxel; Docetaxel; Irinotecan
    PhasePhase 3
    Registry statusCompleted

  • Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

    NCT02192359 · start 2016-04-05

    Registered record
    Registry ID
    NCT02192359
    Conditions
    Recurrent Anaplastic Astrocytoma; Recurrent Anaplastic Oligoastrocytoma; Recurrent Anaplastic Oligodendroglioma; Recurrent Glioblastoma; Recurrent Gliosarcoma; Recurrent Malignant Glioma; Recurrent WHO Grade III Glioma
    Interventions
    Carboxylesterase-expressing Allogeneic Neural Stem Cells; Irinotecan; Irinotecan Hydrochloride; Laboratory Biomarker Analysis; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2016-04-05
    Completion
    2026-09-25
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Anaplastic Astrocytoma; Recurrent Anaplastic Oligoastrocytoma; Recurrent Anaplastic Oligodendroglioma; Recurrent Glioblastoma +3 more
    InterventionCarboxylesterase-expressing Allogeneic Neural Stem Cells; Irinotecan; Irinotecan Hydrochloride; Laboratory Biomarker Analysis +1 more
    PhasePhase 1
    Registry statusActive not recruiting